Research / Clinical
Summary
|
|
 |
Jack Bui, MD, PhD
Assistant Professor, Pathology
Cancer Biology Program
Contact by Email
|
Diseases/Research Topics
Immunotherapy, Innate Immune System, Natural Killer Cells, T-regulatory Cells, Tumor immunology, Tumor Recognition
Dr. Bui's laboratory is interested in how the innate immune system recognizes developing tumor cells. Toward this end, they have generated a bank of tumor cell lines which they believe are enriched in recognition structures that activate innate immune components, including natural killer (NK) cells and macrophages. Bui and his colleagues hope to understand the molecular basis of this recognition.
They also have focused on a family of ligands for the NK cell receptor NKG2D. These NKG2D ligands are highly expressed on tumors, virally infected cells, and in certain autoimmune diseased tissues. They have shown that the NKG2D ligand H60 is regulated by the interferons and may function in this aspect to modulate the immune system. They are actively pursuing the regulation of H60 during carcinogenesis in order to understand how recognition structures might be acquired during the transformation process. A related interest is in how T-regulatory cells inhibit the immune response to tumors. They have shown that these cells accumulate in both progressively growing and rejecting tumors. We plan to identify the mechanisms by which T-regulatory cells become activated in certain tumors for clinical benefit.
Update Summary via ONcLINE (password required)
Click here to request a
new or forgotten password
|
